Myocardial deformation links combined liraglutide-empagliflozin therapy with improved cardiovascular and economic outcomes in type 2 diabetes: a 6-year study.
Аннотация
AIMS: We investigated whether the early favourable effects of combined GLP-1 receptor agonist (GLP-1RA) and SGLT2 inhibitor (SGLT2i) therapy in left ventricular deformation is associated with long-term cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). We also addressed the healthcare costs.
METHODS AND
RESULTS
We enrolled 336 consecutive participants with T2DM, aged 60 ± 10 years old, 252/336 (75%) were males and were categorized into four groups: insulin, liraglutide, empagliflozin, and liraglutide+ empagliflozin. We measured at baseline and at 6 months left ventricular global longitudinal strain (LVGLS) via echocardiography. Patients were followed for 6 years and we recorded the incidence of composite endpoint of non-fatal cardiovascular events (myocardial infarction, heart failure hospitalization, ischaemic stroke, and coronary revascularization). Multivariable Cox regression models were built to assess associations between treatment groups, LVGLS changes, and outcomes. A cost analysis was also conducted. At 6 months LVGLS increased significantly (P = 0.020), with the greatest improvement observed in the combination group compared with insulin, GLP-1RA, and SGLT2i groups (P < 0.05). At 6-year follow-up, 91 events were recorded. Combination therapy was associated with the lowest risk of events (insulin vs. combination: HR = 4.36, 95% CI: 2.04-9.33, P < 0.001; GLP1-RA vs. combination: HR = 2.45, 95% CI: 1.06-5.64, P = 0.035; SGLT2i vs. combination: HR = 3.07, 95% CI: 1.38-6.81, P = 0.006). In combination group, improvement of LVGLS independently predicted reduced event risk (HR = 0.89, 95% CI: 0.79-0.98, P = 0.040). Combination group demonstrated the lowest mean cost per patient per month (insulin: 691€, 95% CI: 472-911; GLP1-RA: 224€, 95% CI: 44-404; SGLT2i: 528€, 95% CI: 305-751; Combination: 175€, 95% CI: 30-321).
CONCLUSION
Combined GLP-1RA and SGLT2i therapy is associated with early improvement in myocardial deformation, which translates into reduced long-term cardiovascular risk and favourable economic outcomes. ClinicalTrials.gov Identifier: NCT03878706.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.